Umeclidinium Bromide is a long-acting muscarinic antagonist (LAMA) used in the maintenance treatment of chronic obstructive pulmonary disease (COPD) by blocking muscarinic acetylcholine receptors to relax… Read more

![Chemical structure of (1-Azabicyclo[2.2.2]oct-4-yl)(diphenyl)methanol](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F461648-39-5-1-Azabicyclo2.2.2oct-4-yldiphenylmethanol.png&w=3840&q=75)




![Chemical structure of 4-([1,1'-Biphenyl]-4-yl(hydroxy)(phenyl)methyl)-1-(2-(benzyloxy)ethyl)quinuclidin-1-ium Bromide](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F2253743-40-5-4-11-Biphenyl-4-ylhydroxyphenylmethyl-1-2-benzyloxyethylquinuclidin-1-ium-Bromide.png&w=3840&q=75)

![Chemical structure of [(2-Bromoethyloxy)methyl]benzene](/_next/image?url=https%3A%2F%2Fassets.splendidlab.com%2F1462-37-9-2-Bromoethyloxymethylbenzene.png&w=3840&q=75)






















Umeclidinium Bromide is a long-acting muscarinic antagonist (LAMA) used in the maintenance treatment of chronic obstructive pulmonary disease (COPD) by blocking muscarinic acetylcholine receptors to relax airway smooth muscle. This category provides a comprehensive range of high-quality reference standards essential for stringent pharmaceutical analysis and regulatory compliance. Laboratories rely on these materials—including parent API, pharmacopeial and non-pharmacopeial impurities, degradation products, and metabolites—for rigorous method validation, impurity profiling, and quality control. Furthermore, the inclusion of stable isotope labelled compounds facilitates precise quantitative analysis, such as mass spectrometry-based assays, by serving as internal standards. These compounds are critical for identifying and quantifying potential degradation products, such as those arising from hydrolysis or oxidation, ensuring that analytical methods accurately assess the drug’s potency, stability, and safety throughout its shelf life.